441 related articles for article (PubMed ID: 27992319)
21. The role of fibroblast growth factors and their receptors in prostate cancer.
Kwabi-Addo B; Ozen M; Ittmann M
Endocr Relat Cancer; 2004 Dec; 11(4):709-24. PubMed ID: 15613447
[TBL] [Abstract][Full Text] [Related]
22. Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling.
Agrawal S; Maity S; AlRaawi Z; Al-Ameer M; Kumar TKS
Curr Drug Targets; 2021; 22(2):214-240. PubMed ID: 33045958
[TBL] [Abstract][Full Text] [Related]
23. Approaches targeting the FGF-FGFR system: a review of the recent patent literature and associated advanced therapeutic agents.
Herbert C; Lassalle G; Alcouffe C; Bono F
Pharm Pat Anal; 2014; 3(6):585-612. PubMed ID: 25489913
[TBL] [Abstract][Full Text] [Related]
24. Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics.
Chandana SR; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2020 Dec; 29(12):1413-1429. PubMed ID: 33074030
[TBL] [Abstract][Full Text] [Related]
25. De-regulated FGF receptors as therapeutic targets in cancer.
Knights V; Cook SJ
Pharmacol Ther; 2010 Jan; 125(1):105-17. PubMed ID: 19874848
[TBL] [Abstract][Full Text] [Related]
26. Blocking the FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer therapy.
Giacomini A; Chiodelli P; Matarazzo S; Rusnati M; Presta M; Ronca R
Pharmacol Res; 2016 May; 107():172-185. PubMed ID: 27013279
[TBL] [Abstract][Full Text] [Related]
27. FGF/FGFR signaling in bone formation: progress and perspectives.
Marie PJ; Miraoui H; Sévère N
Growth Factors; 2012 Apr; 30(2):117-23. PubMed ID: 22292523
[TBL] [Abstract][Full Text] [Related]
28. Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy.
Heinzle C; Sutterlüty H; Grusch M; Grasl-Kraupp B; Berger W; Marian B
Expert Opin Ther Targets; 2011 Jul; 15(7):829-46. PubMed ID: 21375471
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
Hierro C; Rodon J; Tabernero J
Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment.
Liu G; Chen T; Ding Z; Wang Y; Wei Y; Wei X
Cell Prolif; 2021 Apr; 54(4):e13009. PubMed ID: 33655556
[TBL] [Abstract][Full Text] [Related]
31. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
32. Advances and challenges in targeting FGFR signalling in cancer.
Babina IS; Turner NC
Nat Rev Cancer; 2017 May; 17(5):318-332. PubMed ID: 28303906
[TBL] [Abstract][Full Text] [Related]
33. FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma.
Tamburello M; Altieri B; Sbiera I; Sigala S; Berruti A; Fassnacht M; Sbiera S
Endocrine; 2022 Sep; 77(3):411-418. PubMed ID: 35583844
[TBL] [Abstract][Full Text] [Related]
34. FGF receptor gene expression and its regulation by FGF signaling during early zebrafish development.
Ota S; Tonou-Fujimori N; Tonou-Fujimori N; Nakayama Y; Ito Y; Kawamura A; Yamasu K
Genesis; 2010 Dec; 48(12):707-16. PubMed ID: 20960516
[TBL] [Abstract][Full Text] [Related]
35. Targeting fibroblast growth factor pathways in endometrial cancer.
Winterhoff B; Konecny GE
Curr Probl Cancer; 2017; 41(1):37-47. PubMed ID: 28041631
[TBL] [Abstract][Full Text] [Related]
36. Responsiveness of developing dental tissues to fibroblast growth factors: expression of splicing alternatives of FGFR1, -2, -3, and of FGFR4; and stimulation of cell proliferation by FGF-2, -4, -8, and -9.
Kettunen P; Karavanova I; Thesleff I
Dev Genet; 1998; 22(4):374-85. PubMed ID: 9664689
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic uses of FGFs.
Zhang J; Li Y
Semin Cell Dev Biol; 2016 May; 53():144-54. PubMed ID: 26369258
[TBL] [Abstract][Full Text] [Related]
38. Altered FGF signalling in congenital craniofacial and skeletal disorders.
Moosa S; Wollnik B
Semin Cell Dev Biol; 2016 May; 53():115-25. PubMed ID: 26686047
[TBL] [Abstract][Full Text] [Related]
39. FGFR-targeted therapeutics for the treatment of breast cancer.
De Luca A; Frezzetti D; Gallo M; Normanno N
Expert Opin Investig Drugs; 2017 Mar; 26(3):303-311. PubMed ID: 28121208
[TBL] [Abstract][Full Text] [Related]
40. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]